
Carasent prel. Q2 - Soft Q2 causing revised 2025 targets – largely aligning with our unrevised forecasts

Redeye comments on Carasent's preliminary Q2 figures, the revised 2025 targets, and the new mid-term targets.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Carasent prel. Q2 - Soft Q2 causing revised 2025 targets – largely aligning with our unrevised forecasts](#)